Current data with bexarotene (Targretin®) in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 4, Issue 4, 2003, Pages 210-212

  DeGrendele, Heather ^a   Belani, Chandra P ^a   Pass, Harvey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEXAROTENE; CARBOPLATIN; CISPLATIN; ISOTRETINOIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RETINOL PALMITATE;

ADVANCED CANCER; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; EXFOLIATIVE DERMATITIS; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERLIPIDEMIA; HYPOTHYROIDISM; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NAUSEA; PANCREATITIS; VOMITING;

EID: 0037870308     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70280-7     Document Type: Article

References (11)

1. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 1984; 73:1381-1387.
2. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605-618.
3. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11:1216-1222.
4. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977-986.
5. Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancers. Annu Rev Med 2002; 53:223-243.
6. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56:5566-5570.
7. Bischoff ED, Gottardis MM, Moon TE, et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58:479-484.
8. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15:790-795.
9. Rizvi NA, Marshall JL, Dahut W, et al. A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999; 5:1658-1664.
10. Khuri FR, Rigas JR, Figlin RA, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2001; 19:2626-2637.
11. Rizvi NA, Hawkins MJ, Eisenberg PD, et al. Placebo-controlled trial of bexarotene, a retinoid X receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2001; 2:210-215.